Epidemiologie und Therapie von erwachsenen Patienten mit atopischer Dermatitis. Analyse von Längsschnittdaten der gesetzlichen Krankenversicherung
Related Research units
Abstract
BACKGROUND: The goal was to report incidence, prevalence, and treatment patterns in adult atopic dermatitis (AD) patients in the German statutory health insurance system.
PATIENT AND METHODS: Anonymized claims data were evaluated at patient level for 3.3 million persons insured by six different statutory health insurance companies (SHI). Patients for whom the ICD-10 diagnosis code L20 (AD) was applied at least twice were analyzed and data on prescription patterns for AD were reported for the years 2011-2015.
RESULTS: AD prevalence in adults was 1.6-1.9% in 2012-2015. Annual incidence was 0.28%. In Q3/Q4 2015, 44.2% of the adult population with AD diagnosis by a dermatologist received prescriptions for AD medications: 1.6% low-potency topical glucocorticoids (without previous prescription of systemic drugs), 46.9% moderate or high-potency topical glucocorticoids or topical calcineurin inhibitors, 23.9% current systemic therapy (systemic glucocorticoids, ciclosporin, methotrexate, azathioprine, mycophenolate mofetil) and 27.6% systemic therapy in the past.
CONCLUSIONS: The AD prevalence estimate was in the range of previous reports (1.35-4%) that used different methodologies. Based on treatment proxy, it appeared that almost more than half of AD patients treated with prescription ready-to-use drugs had a severe form of AD which required treatment with systemic drugs.
Bibliographical data
Translated title of the contribution | Epidemiology and treatment of adult patients with atopic dermatitis: Analysis of longitudinal data of the statutory health insurance scheme |
---|---|
Original language | German |
ISSN | 0017-8470 |
DOIs | |
Publication status | Published - 11.2021 |
Comment Deanary
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
PubMed | 34379145 |
---|